
Plain Language Summary of ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in **Recurrent or Primary Advanced Endometrial Cancer** 

# Table of Contents




Which patients can enroll?



Why is this study being done?

What medicine is

being tested?



Where can I find

## General information about this study


## Full scientific title:

A Study of Dostarlimab (TSR-042) Plus Carboplatin-Paclitaxel Versus Placebo Plus Carboplatin-Paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Study number: Sponsored by: Study name: NCT03981796 RUBY GlaxoSmithKline Writing and editorial support for this report was provided by Ashfield Healthcare Communications and funded by GlaxoSmithKline

Why is this study being done?

The RUBY study is being done to see if treatment with dostarlimab plus chemotherapy followed by dostarlimab alone is useful in treating endometrial cancer




What medicine is being tested? Dostarlimab is a medicine being tested that is part of a category called

programmed cell death inhibitors (or "PD-1 inhibitors"). These drugs

help your immune system to find and attack cancer cells





immune cells that have PD-1 will find them, and they connect. Through this "handshake," the immune system is told not to attack the cancer cells

Immune cell Cancer cell dostarlimab

the rest of the immune cells that the cancer cells should be attacked


handshake. This immune cell can now signal to



#### Patients must have endometrial cancer


the cancer is first diagnosed


Which patients can enroll?











Patients must be in good enough condition to take care of themselves on their own. For example, they must be able to

Not all patients who meet the criteria shown here will be eligible. More detailed information on who is eligible to participate is

available at https://clinicaltrials.gov/ct2/show/NCT03981796




**Dostarlimab plus chemotherapy** 

How will the trial be conducted?

walk or do light housework or office work





(the treatment being tested)

- Chemotherapy is a drug treatment that uses powerful chemicals to kill cancer cells in your body There are two chemotherapy drugs that are used together in this trial: one is called carboplatin, and the other is called paclitaxel Patients will be placed into the arms randomly (this is what is meant by "randomized")
- In the **control arm**, patients will receive a **placebo** (inactive treatment that looks the same as the
  - dostarlimab treatment) so that neither the patient nor the oncologist know which treatment option the patient is getting (this is what is meant by "double-blind")
- Phase 3 trials compare a new potential treatment against the current standard of care to see if the new treatment is better than the current standard of care ✓ More details on clinical trial phases can be found <u>here</u>
- The trial is enrolling at sites in several countries
- Belarus Greece





Sweden

Standard chemotherapy (the control)



Where can I find more information?

